Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
Nefecon’s addition to China’s NRDL will increase its reach and market share, lifting the drug’s competitive advantage and brand recognition Key Takeaways: Everest Medicines’ Nefecon kidney drug was approved for…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- A McDonald’s Valuation Downsize, and New Medical Plan Additions
-
BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
